InvestorsHub Logo
Followers 5
Posts 593
Boards Moderated 0
Alias Born 06/11/2010

Re: bigduke post# 41385

Monday, 12/16/2013 10:59:42 AM

Monday, December 16, 2013 10:59:42 AM

Post# of 80490
AP26113 - Solving the Treatment Resistance Riddle, www.curetoday.com article, Dec. 8, 2013

Andy Bonnett has been dealing with drug-resistant lung cancer since 2008, but has benefited from clinical trials studying new therapies.

Bonnett has had to deal with further shifts in his cancer makeup and treatment. Last summer, his tumors began showing signs of resistance to Xalkori. He started to feel a return of the pain that marked his original disease. After returning from a kayaking trip for people with cancer, Bonnett underwent new scans, which revealed multiple lesions.

He was eligible, however, for a second clinical trial, one with a new agent, still unnamed, called AP26113, which also targets ALK in a different way. AP26113 seems to be able to make it through the blood-brain barrier, and today, Bonnett’s brain metastases are inactive.

Positive AP26113 progress:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94559928

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.